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Summary
Objective: To evaluate the clinical efficacy of pulmonary resection and postoperative use of a
first-line drug regimen for patients with well-localized, cavitary pulmonary multidrug-resistant
tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB).
Methods: This was a prospective case study set in the National Masan Tuberculosis Hospital in
Masan, Republic of Korea. From February 1998 to May 2004, 19 patients with well-localized,
cavitary pulmonary MDR-TB or XDR-TB were enrolled and followed prospectively through April
2007. After radical surgical resection, patients were treated with anti-tuberculous therapy
consisting of isoniazid (H), rifampin (R), ethambutol (E), pyrazinamide (Z), and streptomycin
(S) (3HREZS/3HRES/6HRE).
Results: All recovered isolates of Mycobacterium tuberculosis were resistant to isoniazid and
rifampin, and to amean of 4.7 anti-tuberculous drugs (range 2—8 drugs). Seventeen patients had
MDR-TB and two had XDR-TB. Surgical procedures included: lobectomy (14 patients), lobectomy
plus segmentectomyorwedge resection (four patients), andpneumonectomy (onepatient). The
median time to postoperative sputum smear and culture conversion was 2 days (range 1—23
days). Fifteen (78.9%) subjects, including both with XDR-TB, had durable cures (mean follow-up
period 53.2 months). One patient failed to convert her sputum and was successfully switched to
second-line therapy. Another patient developed active disease again 68 months after cure,
likely due to re-infection with a newM. tuberculosis strain. Two patients were lost to follow-up
after hospital discharge.* Corresponding author. Tel.: +82 55 249 3791; fax: +82 55 242 1135.
E-mail address: pulmo116@nmh.go.kr.com (S.-K. Park).
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doi:10.1016/j.ijid.2008.06.001
Conclusion: Resectional lung surgery combined with isoniazid- and rifampin-based anti-tubercu-
lous chemotherapy can be an effective treatment strategy for patients with well-localized,
cavitary pulmonary MDR-TB and XDR-TB.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Multidrug-resistant tuberculosis (MDR-TB), defined as in vitro
resistance to at least both isoniazid and rifampin, has become
an emerging global public health crisis.1 Strains of multidrug-
resistant Mycobacterium tuberculosis are often resistant to
other anti-tuberculous agents in addition to isoniazid and
rifampin. When such an isolate is resistant to any second-line
injectable agent (e.g., amikacin, capreomycin, or kanamy-
cin) and any fluoroquinolone, the strain is termed extensively
drug-resistant tuberculosis (XDR-TB).2 In Korea, there is a
high burden of both MDR-TB and XDR-TB. Between 2000 and
2004, among 11 939 clinical samples reported to the World
Health Organization/International Union Against Tuberculo-
sis and Lung Disease (WHO/IUATLD) Supra-National Refer-
ence Laboratory Network, 1298 (10.9%) were MDR-TB and, of
these, 15.4% were XDR-TB.3 The management of MDR-TB and
XDR-TB requires extended treatment and expensive and
potentially toxic drug regimens, and often results in higher
rates of treatment failure and death compared to drug-
sensitive disease.4—7 Reported cure or treatment completion
rates for MDR-TB using second-line agents have ranged from
44% to 83%.8—13 Treatment failure is especially common with
patients co-infected with XDR-TB and HIV, where mortality
approaches 100%.14
In the past decade, surgical intervention has re-emerged
as an important adjunct in the management of MDR-TB.15—18
Lung resection combined with anti-tuberculous chemother-
apy for MDR-TB has shown success rates of 89—96%.19—21 With
increasing rates of XDR-TB worldwide, resectional surgery
will likely become increasingly utilized in these patients with
very limited chemotherapeutic options. At our institution,
we have observed that many patients treated for MDR-TB and
XDR-TB with second- and third-line agents were intolerant to
their drugs, leading to treatment failure or default after
discharge when they could not be covered by directly
observed treatment. From this experience, we postulated
an improved or, at least, comparable outcome might be
achieved using less toxic and better-tolerated first-line drugs
as postoperative adjunctive treatment. In order to prove this
hypothesis, we conducted a prospective case study of 19
patients with pulmonary MDR-TB or XDR-TB and well-loca-
lized, cavitary disease who received radical surgical inter-
vention combined with a postoperative first-line drug
regimen consisting of isoniazid (H), rifampin (R), pyrazina-
mide (Z), ethambutol (E), and streptomycin (S).
Methods
This was a prospective case study. All patients were treated
at the National Masan Tuberculosis Hospital (NMTH) in Masan,
Republic of Korea. The hospital is a 430-bed facility that
serves as a national referral center for individuals with
recurrent and/or drug-resistant tuberculosis. Approximately95% of hospitalized patients have pulmonary disease, and
about 50% have MDR-TB. Anti-tuberculous agents typically
used to treat MDR-TB at NMTH, as part of standardized or
individualized combination regimens, include pyrazinamide,
ethambutol, prothionamide, cycloserine, streptomycin or
kanamycin, para-aminosalicylic acid, and ofloxacin.
The Institutional Review Board of NMTH approved this
study and informed consent was obtained from all partici-
pants and one of their family members before entry into the
study. One of the authors was responsible for obtaining
informed consent from all study participants, and this
involved explaining to each patient and his/her family, in
detail, the purpose of this study, the risk of operation, and
the potential necessity of changing the drug regimen to
second-line drugs during the course of postoperative che-
motherapy. In most cases, this required at least three inter-
views. The final decision to participate in this study was left
entirely to the patients.
Between February 1998 and May 2004, 107 patients with
MDR-TB underwent some type of pulmonary surgery at NMTH.
All patients had preoperative chest X-rays and high-resolu-
tion chest computed tomography (HRCT). In order to confirm
radical resectability, HRCT was performed in each patient
within at least one month before operation, and one of the
authors examined the lung intra-operatively by direct palpa-
tion in order to evaluate for any other lesion(s) that could not
be detected by HRCT prior to surgery. Where radical removal
of the lesion was not considered feasible, patients were
excluded from the study. Eighty-three cases had radical
resectional surgery and received second-line anti-tubercu-
lous therapy before and after surgery. Five cases were not
considered to be radically resectable at the time of surgical
lung examination and were excluded from the study and
treated with second-line anti-tuberculous drugs postopera-
tively. The remaining 19 subjects were enrolled as the study
cohort. All of these patients were HIV-seronegative and were
shedding M. tuberculosis resistant to both isoniazid and
rifampin at the time of diagnosis. All had preoperative chest
X-rays and HRCT that demonstrated well-localized, cavitary
pulmonary tuberculosis that was confined to only the portion
of lung that was subsequently removed surgically. Two sub-
jects were believed to have primary MDR-TB, while 17 had
secondary or acquired MDR-TB according to their treatment
history and drug susceptibility testing results over time.
Preoperative sputum acid-fast bacilli (AFB) smear status
was positive in 10 subjects and negative in nine. For the
latter group, each had chest X-rays that demonstrated one or
more thick-walled cavities, and each also had a history of one
or more episodes of active tuberculosis in the same anatomic
area. None of the study subjects had ever received any
second-line anti-tuberculous chemotherapy for their disease
previously.
After resectional surgery, postoperative regimens for all
19 patients consisted of 3HRZES/3HRES/6HRE, even for docu-
mented MDR-TB, rather than other second- and third-line
Table 2 Rates of resistance for anti-tuberculous drugs
Drug % Resistant (No. resistant/total)
Isoniazid 100 (19/19)
Rifampin 100 (19/19)
Ethambutol 73.7 (14/19)
Para-aminosalicylic acid 47.4 (9/19)
Streptomycin 36.8 (7/19)
Pyrazinamide 26.3 (5/19)
Ofloxacin 26.3 (5/19)
Prothionamide 21.1 (4/19)
Cycloserine 15.8 (3/19)
Kanamycin 21.1 (4/19)
172 S.-K. Park et al.agents in the belief that such therapy would minimize drug
adverse events and optimize tolerance and adherence. After
operation, sputum smears and cultures were obtained every
day for one week, then every second week for one month,
and then monthly for the entire follow-up period. Chest X-
rays were obtained every month and HRCT was obtained
twice, i.e., at 6 months after surgery and at the end of
chemotherapy. Postoperatively, sputum negativity was
defined as serially-negative sputum smears and cultures.
Drug susceptibility testing of all M. tuberculosis strains
was performed in our laboratory using an absolute concen-
tration method described by Canetti and colleagues,22,23
using Loewenstein—Jensen (L—J) medium. Drugs and their
critical concentrations for resistance were as follows: iso-
niazid 0.2 mg/ml, rifampin 40 mg/ml, ethambutol 2 mg/ml,
streptomycin 10 mg/ml, kanamycin 40 mg/ml, prothionamide
40 mg/ml, cycloserine 30 mg/ml, para-aminosalicylic acid
1 mg/ml, ofloxacin 2 mg/ml. Pyrazinamide susceptibility
was determined using a pyrazinamidase test. Resistance
was indicated by the growth of more than 1% of the colonies
on drug-containing medium.
Results
Patient characteristics and clinical outcomes for all 19
patients are shown in Table 1. The male:female ratio for
the study cohort was 15:4. The mean patient age was 31.1
years (range 20—46 years). Recovered isolates of M. tuber-
culosiswere resistant to a mean of 4.7 anti-tuberculous drugs
(range 2—8 drugs). All 19 study isolates displayed in vitro
resistance to isoniazid and rifampin, and XDR-TB was present
in two cases. Resistance to the first-line agents ethambutol,
streptomycin, and pyrazinamide was seen in 73.7%, 36.8%,
and 26.3% of isolates, respectively; 10 of 19 subjects (52.6%)
had isolates that were resistant to at least two of these three
agents. Three patients had isolates of M. tuberculosis that
were susceptible to all three of these agents. Some strains
showed resistance to second-line anti-tuberculous drugs that
the patients had not knowingly been exposed to previously.
Resistance rates for second-line drugs were as follows: para-
aminosalicylic acid 47.4%, ofloxacin 26.3%, kanamycin 21.1%,
prothionamide 21.1%, and cycloserine 15.8% (Table 2).
Surgical procedures included lobectomy (14 patients),
lobectomy plus segmentectomy or wedge resection (four
patients), and pneumonectomy (one patient). There were
no significant postoperative complications such as bleeding,
empyema, and bronchopleural fistula. Ten patients (52.6%)Table 1 Clinical characteristics and postoperative out-
comes of 19 patients with multidrug-resistant or extensively
drug-resistant TB
Sex (male:female) 15:4
Age (years) 31.1  6.8
Disease duration before operation (months) 8.5  4.6
Number of prior TB chemotherapy courses 0.8  0.6
Number of resistant drugs 4.7  1.8
Follow-up (months) 53.2  29.1
Default rate (%) 10.5 (2/19)
Conversion rate (%) 94.7 (18/19)had preoperative sputum AFB smear and/or culture positiv-
ity; for these individuals, the median time to sputum smear
and culture conversion was 2 days (range 1—3 days for smear
and 1—23 days for culture), and each remained serially
smear-negative after surgery.
Fifteen (78.9%) patients had durable cures (mean follow-
up period 53.2 months). One of these subjects died from an
unknown cause other than pulmonary tuberculosis one and a
half years after treatment completion. One patient failed to
convert her sputum smear and culture even after seven
months of treatment postoperatively. Drug sensitivity testing
revealed her isolate to be resistant to isoniazid, rifampin,
ethambutol, para-aminosalicylic acid, and streptomycin. Her
drug regimen was changed to second-line drug therapy con-
sisting of prothionamide, pyranzinamide, ofloxacin, cyclo-
serine, and kanamycin and sputum conversion was achieved
four months later. Another patient relapsed during the fol-
low-up period, 68 months after cure. He was retreated with
second-line drugs and achieved a second cure after an addi-
tional 24 months of chemotherapy. The remaining two
patients interrupted their medications and were lost during
the follow-up period (Table 3).
Discussion
The successful treatment of any infectious disease involves a
delicate balance of host and pathogen processes. Surgery for
MDR-TB and XDR-TB can best be considered as a neo-adjuvant
‘debulking’ procedure to remove a major, focal burden of
tubercle bacilli contained within necrotic and non-viable
lung tissue. In one study, resected tissue culture demon-
strated mycobacterial growth even from patients who were
sputum AFB smear-negative preoperatively.24 In the present
study, we also performed tissue culture for nine subjects with
sputum culture-negativity before surgery, and all of them had
tissue that was both smear- and culture-positive. Incomplete
resection of tuberculous lesions, especially cavities, but also
nodules, bullae, microcavities, or fibrotic areas, is one of the
risk factors for disease relapse.25 These prior studies and the
excellent outcome in our study exemplify the benefit of
complete or radical removal of all tuberculous lesions for
cure in both MDR- and XDR-TB patients.
In the human lung, selection of drug-resistance mutations
in M. tuberculosis occurs predominantly within lung cavities
in which high bacterial loads, active mycobacterial replica-
tion, and reduced exposure to host defense mechanisms have
Table 3 Clinical profiles and outcomes for 19 multidrug-resistant or extensively drug-resistant TB subjects who received radical
surgical resection and a regimen composed of first-line anti-tuberculous drugs
Subject No. Sex/age (years) Date of diagnosis Resistant drugsa Date of surgery Type of surgeryb Outcomec
1 M/32 1997-09-30 HERO 1998-02-11 RUL R
2 M/37 1997-03-07 HERZ 1998-06-02 RUL D
3 F/36 1997-11-11 HERPS 1998-07-01 LUL + Wedge F
4 M/41 1998-09-07 HERPSK 2000-01-12 RUL C
5 M/30 1999-10-17 HR 2000-02-15 RUL C
6 M/25 2000-08-01 HERPThCS 2001-02-13 RUL C
7 M/28 2001-04-04 HERPThOK 2001-05-29 RUL C
8 M/32 2000-08-09 HERZPO 2001-10-16 LP C
9 F/34 2001-05-16 HERPSK 2002-01-08 LUL C
10 M/24 2001-10-04 HER 2002-03-19 LUL C
11 M/25 2002-07-28 HRS 2002-11-12 LUL C
12 F/29 2002-06-20 HRPThCS 2003-02-25 RUL C
13 M/46 2003-01-21 HR 2003-09-23 RUL C
14 M/20 2002-05-16 HER 2003-09-30 LUL + Seg D
15 M/31 2002-12-01 HETZ 2003-10-20 LUL C
16 M/36 2003-06-01 HERPTh 2004-01-13 RUL C
17 F/23 2003-08-07 HERZPCOK 2004-01-07 RUL + Seg C
18 M/24 2003-08-09 HRO 2004-02-10 RUL + Wedge C
19 M/30 2004-01-04 HRES 2004-05-25 LUL C
a H, isoniazid; E, ethambutol; R, rifampin; Z, pyrazinamide; P, para-aminosalicylic acid; C, cycloserine; Th, prothionamide; O, ofloxacin; S,
streptomycin; K, kanamycin.
b RUL, right upper lobectomy; LUL, left upper lobectomy; LP, left pneumonectomy; Wedge, wedge resection; Seg, segmentectomy.
c R, relapse; D, default; F, failed; C, cure.
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tance display a more diverse clonality of tubercle bacilli than
those with primary drug resistance. Post and colleagues
described genetic polymorphisms in M. tuberculosis isolates
from patients with chronic MDR-TB. In four of 13 HIV-sero-
negative patients (30.8%) with MDR-TB, heterogeneous popu-
lations of bacilli with different resistance mutations, as well
as mixtures of drug-susceptible and drug-resistant geno-
types, were observed.27 The surface of tuberculous cavities
has been characterized as a microenvironment of impaired
immunity. In examining the histopathology and microbiology
of different tuberculous lung lesions, Kaplan and colleagues
found that only at the surface of cavities were numerous
tubercle bacilli present.26 The mutational profile of isolates
found at this location suggested that a single founder strain of
M. tuberculosis may undergo genetic changes during treat-
ment, leading to acquisition of additional drug resistance
independently at discrete physical locales. These authors
postulated that a selective absence of CD4+ and CD8+ T-cells
at the luminal surface, rather than a generalized immuno-
suppression, may prevent direct T-cell-macrophage interac-
tions at the luminal surface of cavities. Such selective
impairment of immunity at local sites could potentially
explain how drug-resistant organisms might be preferentially
distributed within certain portions of the lung. It should be
noted, however, that detailed quantitation of bacillary sub-
populations isolated from different sites in the lung(s), and
precise determination of their levels of resistance, has not
been performed, although such a study could provide useful
information that might direct different drug treatment
approaches, including determining the role, if any, of iso-
niazid and rifampin in cases of MDR-TB and XDR-TB.It may also be that surgical removal of heavily-diseased
lung segments results in partial restoration of immunologic
responses or some change in immunologic milieu in the host,
which can allow the host to more efficiently contain and
eradicate the tuberculous infection, even in the presence of
chemotherapeutic agents that do not have sufficient eradi-
cation activity in vitro against multidrug-resistant M. tuber-
culosis. Partial immune reconstitution of cellular and
cytokine responses are well-described in tuberculosis follow-
ing anti-tuberculous and/or antiretroviral therapy, and these
paradoxical reactions may be so intense as to create newly
discernible foci of disease at previously unrecognized sites of
infection, and which may require short courses of systemic
corticosteroids to suppress the inflammatory responses.28,29
From the literature and our own previous unpublished
surgical experience, we hypothesized that for patients with
well-localized, cavitary tuberculosis that is radiographically
confined to the portion of lung that is removed, microscopic
populations of organisms remaining in the lung(s) after sur-
gical resection may contain only few, if any, drug-resistant
organisms and, thus, might be treated with isoniazid- and
rifampin-based regimens. Our results demonstrate that post-
operative drug therapy including these and other first-line
agents can successfully inhibit growth of any residual infec-
tion in such carefully selected MDR-TB and XDR-TB patients
and lead to durable cure.
It seems likely that the 78.9% long-term cure rate seen in
our series may have been determined, at least in part, by the
varying degrees of susceptibility of M. tuberculosis strains to
pyrazinamide, ethambutol, and/or streptomycin, or activity
of isoniazid and rifampin themselves against MDR-TB.30 Still,
84.2% of study patients were infected with organisms that
174 S.-K. Park et al.were resistant to at least one of the first-line agents other
than isoniazid and rifampin, and 52.6% were resistant to at
least two drugs. This suggests that surgery rather than anti-
microbial drug effect, may have been the most crucial factor
leading to clinical cure in these patients, as does the short
mean time of 2 days to sputum conversion following opera-
tion.
Our study could not identify possible risk factors for
treatment failure or relapse among the participants due to
its small numbers. In one patient who developed active
tuberculosis 68 months later after completion of treatment,
the different antibiograms of his pre- and post-chemotherapy
isolates strongly suggested exogenous re-infection with a
new strain of M. tuberculosis rather than late disease
relapse, although genetic fingerprinting of these isolates
was not performed.31 A cautionary note is that patients
whose primary infection is clearly from a source patient with
known resistant disease are likely to have clonal expansion of
the resistant clone and may, therefore, be less likely to
benefit from the rationale employed in this isoniazid- and
rifampin-based drug regimen.
In using isoniazid and rifampin to treat MDR-TB, we had to
confront several ethical issues. Theoretically, in removing
portions of the lung that contained the entire burden of
disease according to chest CT imaging and manual palpation
of the lung during operation, it is possible that no further
chemotherapy was needed in order to cure infection in these
patients. Analogously, from historical experience during the
pre-antibiotic era we know that adequate drainage of bac-
terial abscesses can sometimes lead to complete cure of
infection without the concomitant use of antimicrobial
drugs. Understandably, however, we did not feel ethically
comfortable in this option. But we do believe, however, that
for individuals with well-demarcated pulmonary tuberculosis
that can be radically removed by surgical intervention, the
effective use of first-line drugs with bactericidal efficacy can
be ethically justified.
In conclusion, resectional lung surgery combined with
isoniazid- and rifampin-based first-line anti-tuberculous che-
motherapy can be an effective treatment strategy for
patients with well-localized, cavitary pulmonary MDR-TB
and XDR-TB.
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